Current Childhood Apraxia of Speech Research Projects

Pharmacological treatment of Childhood Apraxia of Speech

This research investigates whether the drug methylphenidate (MPH, also known as Ritalin) can improve speech and language outcomes in children with apraxia of speech (CAS). This is the first randomised clinical trial to evaluate MPH as a potential treatment for CAS.

Interested in participating? Learn more about our pharmaceutical trial for Childhood Apraxia of Speech.

Genetics of Speech

At present, we have found we can identify a single gene causative for childhood apraxia of speech in around 1 in 3 children. Learning more about the genetic basis of speech disorders will help us more easily identify which children may be at risk of speech disorder, and will allow us to develop more targeted treatments.

Interested in participating? Learn more about our genetics of speech study.

Proudly in partnership with